Qualigen therapeutics, inc. receives nasdaq notice regarding delayed form 10-k filing

Carlsbad, calif., april 21, 2023 (globe newswire) -- qualigen therapeutics, inc. (“qualigen” or “the company,” nasdaq: qlgn), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for orphan drug designation, while also commercializing diagnostics, today reports that on april 20, 2023, it received a letter from the nasdaq stock market llc (“nasdaq”) relating to the company's failure to timely file its annual report on form 10-k for the year ended december 31, 2022 (the “form 10-k”) as required under section 5250(c) of nasdaq rules regarding the qualification, listing and delisting of companies (the “nasdaq listing rules”). on march 31, 2023, the company filed notification of late filing on form 12b-25 (the “form 12b-25”), indicating that the filing of its form 10-k will be delayed until after the completion of the accounting and disclosures related to the company's acquisition of a majority interest in nanosynex, ltd included in its annual report.
QLGN Ratings Summary
QLGN Quant Ranking